NL-OMON35094
Completed
Not Applicable
A Phase 1 Study to Compare the Pharmacokinetics of CAL-101 Capsules to Tablets in Healthy Male Subjects. - CAL-101 BE study.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Blooddisease
- Sponsor
- Calistoga Pharmaceuticals Inc.
- Enrollment
- 15
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- healthy male volunteers
- •\- age between 18 and 65 years (inclusive)
- •\- BMI between 18 and 30 kg/m2
- •\- non heavy or average smoker
- •\- at screening the state of health satisfies the entry requirements
Exclusion Criteria
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor (500 mL or more) within 90 days from the start of the study. In case of donating more than 1\.5 liters of blood in the 10 months prior the start of this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A Phase 1 Study of Olorofim in Healthy Japanese and Caucasian ParticipantsHealthy adult participantsJPRN-jRCT2031230016agata Tsutae24
Completed
Phase 1
A phase I study to assess the pharmacokinetics of a single dose of a slow-release solid injection of EPT1647 in healthy male volunteers/AHealthy male volunteersN/AOther -ACTRN12605000782639Epitan Limited6
Recruiting
Phase 1
MYCATJapanese Patients with Pulmonary MABC DiseaseJPRN-jRCT2031220211Ho Namkoong10
Completed
Not Applicable
A study to evaluate the pharmacokinetic and pharmacodynamic equivalence of HSP-130 and United States-approved Neulasta (Registered Trademark) and European Union-approved Neulasta (Registered Trademark) administered as a single subcutaneous dose to healthy volunteers.The study will be conducted in healthy subjects. Neulasta is indicated for the treatment of cancer chemotherapy-induced neutropenia.Cancer - Any cancerACTRN12615001049561Hospira, Inc.150
Withdrawn
Not Applicable
A Phase 1 Pharmacokinetic-Pharmacodynamic Study of Avelumab (MSB00100718C) in Patients with Previously Treated Advanced Stage Classical Hodgkin*s LymphomaHodgkin's Lymphomalymph node cancer10025319NL-OMON43446Pfizer15